{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:43:42Z","timestamp":1792122222565,"version":"4.4.0"},"reference-count":20,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>The pivotal clinical trials, CARTITUDE-1 and KarMMa-3, showed promising response rates in relapsed and refractory multiple myeloma (RRMM) with use of BCMA-directed CAR T-cell therapy; however, a major challenge is determining suitability in patients who do not meet trial inclusion criteria due to suboptimal organ function. In this multicenter retrospective study, we evaluated the safety and efficacy of BCMA CAR-T therapy in patients with RRMM and renal impairment (RI), defined as creatinine clearance (CrCL) of less than 45 mL\/min. We evaluated 223 patients treated with idecabtagene vicleucel (ide-cel) or ciltacabtagene autoleucel (cilta-cel) between May 2021 and April 2024. Outcomes were compared between baseline RI (11.2%) and normal renal function (nRF) cohorts. Response rates were similar at 1 month (p = 0.09), 3 months (p &gt; 0.9), and 6 months (p = 0.8). Progression-free survival (PFS) was 21.9 months in the RI group compared to 15 months in the nRF group (p = 0.32), while overall survival (OS) was 27.9 months for patients with nRF versus not reached for patients with RI (p = 0.87). Patients with RI had higher rates of immune effector cell-associated neurotoxicity syndrome (ICANS) (60% vs. 19%, p = 0.04) and infections (44% vs. 20%, p = 0.008). We found that BCMA CAR-T demonstrated comparable efficacy in RRMM patients with baseline RI, although these patients exhibited increased rates of neurotoxicity and infections.<\/jats:p>","DOI":"10.3390\/curroncol33020080","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T13:04:46Z","timestamp":1769778286000},"page":"80","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed\/Refractory Multiple Myeloma and Renal Impairment"],"prefix":"10.3390","volume":"33","author":[{"given":"Alma","family":"Habib","sequence":"first","affiliation":[{"name":"Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, USA"},{"name":"US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS 66103, USA"},{"name":"Division of Hematology, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, USA"},{"name":"US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS 66103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2166-2583","authenticated-orcid":false,"given":"Abdullah Mohammad","family":"Khan","sequence":"additional","affiliation":[{"name":"US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS 66103, USA"},{"name":"Division of Hematology, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl","family":"Chang","sequence":"additional","affiliation":[{"name":"US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS 66103, USA"},{"name":"Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC 28204, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2702-8225","authenticated-orcid":false,"given":"Barry","family":"Paul","sequence":"additional","affiliation":[{"name":"US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS 66103, USA"},{"name":"Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC 28204, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5604-4166","authenticated-orcid":false,"given":"Hira","family":"Shaikh","sequence":"additional","affiliation":[{"name":"US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS 66103, USA"},{"name":"Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA 52242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Strouse","sequence":"additional","affiliation":[{"name":"US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS 66103, USA"},{"name":"Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA 52242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0660-3446","authenticated-orcid":false,"given":"Emily","family":"Struble","sequence":"additional","affiliation":[{"name":"US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS 66103, USA"},{"name":"Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA 52242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Vegel","sequence":"additional","affiliation":[{"name":"US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS 66103, USA"},{"name":"Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA 52242, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3168-2521","authenticated-orcid":false,"given":"Zahra","family":"Mahmoudjafari","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, USA"},{"name":"US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS 66103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Umair","family":"Mushtaq","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, USA"},{"name":"US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS 66103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"McGuirk","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6603-185X","authenticated-orcid":false,"given":"Al-Ola","family":"Abdallah","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, USA"},{"name":"US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS 66103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4547-7534","authenticated-orcid":false,"given":"Shebli","family":"Atrash","sequence":"additional","affiliation":[{"name":"US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS 66103, USA"},{"name":"Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC 28204, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reed","family":"Friend","sequence":"additional","affiliation":[{"name":"US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS 66103, USA"},{"name":"Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC 28204, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple Myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajh.70104","article-title":"Parameters Associated With Renal Recovery and Survival in Myeloma Patients With Acute Renal Failure to Cast Nephropathy","volume":"101","author":"Ludwig","year":"2026","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1681\/ASN.2010080857","article-title":"Early reduction of serum-free light chains associates with renal recovery in myeloma kidney","volume":"22","author":"Hutchison","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/14712598.2019.1641196","article-title":"B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma","volume":"19","author":"Tai","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1): A Phase 1b\/2 Open-Label Study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Ailawadhi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Ciltacabtagene Autoleucel versus Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"Dhakal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Rodriguez-Otero, P., and San Miguel, J.F. (2022). Post-CAR-T Cell Therapy (Consolidation and Relapse): Multiple Myeloma. The EBMT\/EHA CAR-T Cell Handbook, Springer.","DOI":"10.1007\/978-3-030-94353-0_34"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1002\/ctm2.346","article-title":"A phase I study of anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma and plasma cell leukemia","volume":"11","author":"Li","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1182\/blood.2024024582","article-title":"Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: Updated KarMMa-3 analyses","volume":"144","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"LBA106","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA106","article-title":"First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma","volume":"41","author":"Dhakal","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_13","first-page":"26886","article-title":"Acute kidney injury in hematological patients treated with CAR-T cells: Risk factors, clinical presentation and impact on outcomes","volume":"14","author":"Russo","year":"2024","journal-title":"Dent. Sci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e14534","DOI":"10.1200\/JCO.2024.42.16_suppl.e14534","article-title":"Risk stratification for immune effector cell-associated neurotoxicity syndrome in patients receiving chimeric antigen receptor T cell therapy","volume":"42","author":"Chishinga","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S210","DOI":"10.1016\/j.jtct.2023.12.273","article-title":"Infectious Complications in Patients with Hematologic Malignancies Receiving CD19 Vs. BCMA Targeted CAR-T Therapy","volume":"30","author":"Abid","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S583","DOI":"10.1093\/ofid\/ofaa439.1291","article-title":"1105. The Burden of Infections Prior to Chimeric Antigen Receptor (CAR) Modified T-cell Therapy Predicts Post-CAR T-cell Infectious Complications","volume":"7","author":"Garner","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"ofae734","DOI":"10.1093\/ofid\/ofae734","article-title":"Risk Factors for Infection-Attributable Mortality in Patients with Staphylococcus aureus Bacteremia: A Competing Risk Analysis","volume":"12","author":"Bae","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/ajh.27056","article-title":"The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL","volume":"98","author":"Rejeski","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e004475","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Naqvi","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jtct.2023.05.012","article-title":"Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy","volume":"29","author":"Davis","year":"2023","journal-title":"Transplant. Cell. Ther."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/2\/80\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T11:52:34Z","timestamp":1770378754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/2\/80"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["curroncol33020080"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33020080","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]}}}